GlassScriptPhysician profile
Ravi Chandran
NPI 1730133547
$13,438.91
in general payments reported to CMS, 2019-2025
31 companies · $10K in 2025
The $10K reported for 2025 was more than what 93% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,228 · 2020: $438 · 2021: $302 · 2022: $456 · 2023: $66.12 · 2024: $909 · 2025: $10K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $7,000 · Travel and Lodging: $3,178 · Food and Beverage: $836.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $7,000.00 |
| Travel and Lodging | $3,178.23 |
| Food and Beverage | $835.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $8,212.09 | 2023-2025 | |
| Olympus Corporation of The Americas | $2,213.28 | 2024-2025 | Single Use Suction Valve (Sterile), Spiration Valve System |
| Insmed, INC. | $565.94 | 2019-2025 | Brinsupri, Arikayce |
| Glaxosmithkline, LLC. | $504.43 | 2019-2025 | Trelegy Ellipta, Arexvy |
| Genentech USA, INC. | $249.69 | 2019-2021 | |
| Actelion Pharmaceuticals US, INC. | $247.24 | 2019-2024 | Uptravi, Opsumit |
| Electromed, INC. | $226.16 | 2021-2025 | Smartvest |
| Boehringer Ingelheim Pharmaceuticals, INC. | $180.99 | 2020-2025 | Ofev |
| Astrazeneca Pharmaceuticals LP | $145.48 | 2019-2025 | Airsupra |
| Philips North America LLC | $98.81 | 2019-2021 | |
| Resmed Corp | $96.81 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $85.44 | 2019-2025 | Keytruda |
| Genzyme Corporation | $76.93 | 2019-2020 | |
| United Therapeutics Corporation | $72.67 | 2019-2021 | |
| Circassia INC. | $54.86 | 2019-2020 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zambon USA LTD. | $54.36 | 2022 | |
| Janssen Pharmaceuticals, INC | $46.89 | 2019-2020 | |
| Viatris Specialty LLC | $43.09 | 2025 | Yupelri |
| Mylan Specialty L.P. | $40.75 | 2021-2024 | Yupelri |
| Verona Pharma, INC. | $33.74 | 2025 | Ohtuvayre |
| Grifols USA, LLC | $31.70 | 2019-2025 | Prolastin-C Liquid |
| Regeneron Healthcare Solutions, INC. | $23.32 | 2025 | Dupixent |
| Inspire Medical Systems, INC. | $22.82 | 2025 | Inspire |
| Pharming Healthcare, INC. | $20.26 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $18.22 | 2022 | |
| Novartis Pharmaceuticals Corporation | $18.02 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $16.45 | 2019 | |
| Gilead Sciences, INC. | $14.76 | 2021 | |
| Fisher & Paykel Healthcare INC | $12.57 | 2020 | |
| Teva Pharmaceuticals USA, INC. | $11.14 | 2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ravi Chandran listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.